174 related articles for article (PubMed ID: 37165917)
1. Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations.
Sato T; Akao K; Sato A; Tsujimura T; Mukai S; Sekido Y
Cancer Med; 2023 Jun; 12(12):13586-13598. PubMed ID: 37165917
[TBL] [Abstract][Full Text] [Related]
2. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
3. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
4. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
[TBL] [Abstract][Full Text] [Related]
5. NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
Yang H; Hall SRR; Sun B; Zhao L; Gao Y; Schmid RA; Tan ST; Peng RW; Yao F
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805359
[TBL] [Abstract][Full Text] [Related]
6. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
[TBL] [Abstract][Full Text] [Related]
7. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
Sekido Y
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565815
[TBL] [Abstract][Full Text] [Related]
9. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.
Tanaka I; Osada H; Fujii M; Fukatsu A; Hida T; Horio Y; Kondo Y; Sato A; Hasegawa Y; Tsujimura T; Sekido Y
Oncogene; 2015 Jan; 34(1):73-83. PubMed ID: 24336325
[TBL] [Abstract][Full Text] [Related]
10. YAP1 is essential for malignant mesothelioma tumor maintenance.
Calvet L; Dos-Santos O; Spanakis E; Jean-Baptiste V; Le Bail JC; Buzy A; Paul P; Henry C; Valence S; Dib C; Pollard J; Sidhu S; Moll J; Debussche L; Valtingojer I
BMC Cancer; 2022 Jun; 22(1):639. PubMed ID: 35689194
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
12. LATS2 is a tumor suppressor gene of malignant mesothelioma.
Murakami H; Mizuno T; Taniguchi T; Fujii M; Ishiguro F; Fukui T; Akatsuka S; Horio Y; Hida T; Kondo Y; Toyokuni S; Osada H; Sekido Y
Cancer Res; 2011 Feb; 71(3):873-83. PubMed ID: 21245096
[TBL] [Abstract][Full Text] [Related]
13. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
14. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
Gao Y; Yi J; Zhang K; Bai F; Feng B; Wang R; Chu X; Chen L; Song H
J Exp Clin Cancer Res; 2017 Nov; 36(1):161. PubMed ID: 29145896
[TBL] [Abstract][Full Text] [Related]
16. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
[TBL] [Abstract][Full Text] [Related]
17. CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.
Ito T; Nakamura A; Tanaka I; Tsuboi Y; Morikawa T; Nakajima J; Takai D; Fukayama M; Sekido Y; Niki T; Matsubara D; Murakami Y
Cancer Sci; 2019 Jul; 110(7):2284-2295. PubMed ID: 31069869
[TBL] [Abstract][Full Text] [Related]
18. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
19. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
Sato T; Sekido Y
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
Sekido Y
Pathol Int; 2011 Jun; 61(6):331-44. PubMed ID: 21615608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
